Kidney Cancer News and Research RSS Feed - Kidney Cancer News and Research

Kidney cancer is usually defined is a cancer that originates in the kidney. The two most common types of kidney cancer, reflecting their location within the kidney, are renal cell carcinoma (RCC) and urothelial cell carcinoma (UCC) of the renal pelvis.
Lin28 gene may hold clues to regeneration of damaged kidneys in adults

Lin28 gene may hold clues to regeneration of damaged kidneys in adults

​Nearly one-third of cases of Wilms tumor, a pediatric cancer of the kidney, are linked to a gene called Lin28, according to research from Boston Children's Hospital. Mice engineered to express Lin28 in their kidneys developed Wilms tumor, which regressed when Lin28 was withdrawn, indicating that strategies aimed at blocking or deactivating the gene hold therapeutic promise for children with Wilms. [More]
Misplaced protein provides promising drug target for kidney cancer

Misplaced protein provides promising drug target for kidney cancer

The shortage of oxygen, or hypoxia, created when rapidly multiplying kidney cancer cells outgrow their local blood supply can accelerate tumor growth by causing a nuclear protein called SPOP-which normally suppresses tumor growth-to move out of the nucleus to the cytoplasm, where it has the opposite effect, promoting rapid proliferation. [More]

Renal mass biopsy rates increasing in kidney cancer

Rates of renal mass biopsy have been historically low in patients with kidney cancer, but are steadily rising, shows an analysis of Medicare data. [More]
Patient with advanced bladder cancer shows complete response to everolimus and pazopanib drugs

Patient with advanced bladder cancer shows complete response to everolimus and pazopanib drugs

A patient with advanced bladder cancer experienced a complete response for 14 months to the drug combination everolimus and pazopanib in a phase I trial, and genomic profiling of his tumor revealed two alterations that may have caused this exceptional response, according to a study published in Cancer Discovery, a journal of the American Association for Cancer Research. [More]
Survival rates for bladder cancer in UK are falling, confirms new study

Survival rates for bladder cancer in UK are falling, confirms new study

Of the top 10 cancers in the UK, bladder cancer is only one where survival rates have been shown to be getting worse. New figures published this month in the Journal of Clinical Urology confirm in a study of cases of bladder cancer in England over a 19 year period (from 1990 until 2009) that survival rates here in the UK are falling and are worse than in than in other European countries with similar incidence rates. [More]

Partial nephrectomy may offer younger renal cancer patients survival advantage

Partial nephrectomy may offer younger patients with localized renal cancer a distinct survival advantage compared with the complete removal of the kidney, US research suggests. [More]

Advanced age should not preclude sunitinib use for mRCC

Elderly kidney cancer patients benefit from sunitinib therapy just as much as their younger counterparts, a retrospective analysis of six clinical trials shows. [More]
Idiopathic pulmonary fibrosis could soon be diagnosed without the need for surgical lung biopsy

Idiopathic pulmonary fibrosis could soon be diagnosed without the need for surgical lung biopsy

People who have suspected idiopathic pulmonary fibrosis without typical patterns on high resolution computed tomography scans could in future be spared the substantial risks of lung biopsy and be given a confident diagnosis of IPF based on clinical and radiological findings alone, according to new research published in The Lancet Respiratory Medicine. [More]
Vaccine-based clinical trial to improve survival outcomes of kidney cancer patients

Vaccine-based clinical trial to improve survival outcomes of kidney cancer patients

The Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute has opened a novel Phase III, vaccine-based clinical trial aimed at providing kidney cancer patients long-term control of their disease. [More]
Researchers personalize drug treatments for cholangiocarcinoma using genomic sequencing

Researchers personalize drug treatments for cholangiocarcinoma using genomic sequencing

Physicians at Mayo Clinic's Individualized Medicine Clinic and researchers at the Translational Genomics Research Institute (TGen) have personalized drug treatments for patients with cholangiocarcinoma using genomic sequencing technologies. [More]
Advanced melanoma treatments: an interview with Dr. James Larkin, Consultant Medical Oncologist, The Royal Marsden

Advanced melanoma treatments: an interview with Dr. James Larkin, Consultant Medical Oncologist, The Royal Marsden

Advanced melanoma affects around 2,000 people per year in the UK. Advanced melanoma describes a melanoma that has spread from its site of origin to other areas of the body. [More]

Study suggests effective way to counter influenza infections

McGill researchers, led by Dr. Maya Saleh of the Department of Medicine, have identified an enzyme, cIAP2 that helps the lungs protect themselves from the flu by giving them the ability to resist tissue damage. "It's a discovery that offers exciting new avenues for controlling influenza, since until now attempts to target the virus itself have proven challenging, especially in the face of emerging new strains of the virus," says Saleh, who is also a researcher at the Research Institute of the McGill University Health Centre. [More]

RPCI enrolls patients in clinical trials of immunotherapy approaches for treating genitourinary cancers

Researchers at the Roswell Park Cancer Institute Center for Immunotherapy are enrolling patients in three different clinical trials of novel immunotherapy approaches for treating genitourinary cancers. [More]
Transgene welcomes SillaJen’s intention to acquire Jennerex

Transgene welcomes SillaJen’s intention to acquire Jennerex

Transgene SA (Paris:TNG) said today that it welcomed the announcement by SillaJen, Inc. of its intention to acquire Jennerex, Inc. and has consequently given its consent to the definitive merger agreement. [More]
SillaJen executes definitive merger agreement to acquire Jennerex

SillaJen executes definitive merger agreement to acquire Jennerex

SillaJen, Inc., a privately-held biotherapeutics and contract research company focused on the development of targeted biological products for cancer, announced today that it had executed a definitive merger agreement to acquire San Francisco-based Jennerex, Inc. [More]
Dysregulation of epigenetic marks may play role in chronic kidney disease, shows study

Dysregulation of epigenetic marks may play role in chronic kidney disease, shows study

The research of physician-scientist Katalin Susztak, MD, PhD, associate professor of Medicine in the Renal Electrolyte and Hypertension Division, at the Perelman School of Medicine, University of Pennsylvania, strives to understand the molecular roots and genetic predisposition of chronic kidney disease. [More]

CTCA doctor presents cutting-edge treatments for cancer patients to medical colleagues

Walter Quan, Jr., MD Chief of Medical Oncology and Director of Immunotherapy at Cancer Treatment Centers of America- Western Regional Medical Center is presenting new findings that are showing a major benefit to cancer patients. [More]
Gene mutated in rare hereditary disorder also prevents mTORC1 pathway activation

Gene mutated in rare hereditary disorder also prevents mTORC1 pathway activation

Whitehead Institute scientists report that the gene mutated in the rare hereditary disorder known as Birt-Hogg-Dub- cancer syndrome also prevents activation of mTORC1, a critical nutrient-sensing and growth-regulating cellular pathway. [More]
Nanopharmaceutical drug shows promise for cancers that resist antiangiogenic drugs

Nanopharmaceutical drug shows promise for cancers that resist antiangiogenic drugs

The nanopharmaceutical drug CRLX101 is showing promise as a potential new treatment for cancers that develop resistance to antiangiogenic drugs and radiation therapy, according to clinical trial results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19 - 23. [More]
Scientists identify 127 mutated genes that appear to drive development of tumors in the body

Scientists identify 127 mutated genes that appear to drive development of tumors in the body

Examining 12 major types of cancer, scientists at Washington University School of Medicine in St. Louis have identified 127 repeatedly mutated genes that appear to drive the development and progression of a range of tumors in the body. The discovery sets the stage for devising new diagnostic tools and more personalized cancer treatments. [More]